DOI: 10.12890/2024_004412

Recurrent intra-stent coronary restenosis in a carrier of non-disease-specific antinuclear antibodies

Authors

  • Benedetta Tomberli Division of Cardiology, Cardiothoracovascular Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
  • Stefano Fumagalli Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
  • Tiziana Cristina Minopoli Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
  • Silvia Menale Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
  • Valentina Scheggi Division of Cardiovascular and Perioperative Medicine, Cardiothoracovascular Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
  • Niccolò Marchionni Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

valentina.scheggi@gmail.com

Keywords

Intracoronary in-stent restenosis, coronary vasculitis, autoimmune disease

Abstract

Intracoronary in-stent restenosis (ISR) is a phenomenon that generally occurs between 3 and 6 months after stent placement. With the introduction of drug-eluting stents (DES), the incidence of ISR has decreased but not disappeared. We report a case of reiterant in-stent restenosis of an 81-year-old female patient who underwent multiple percutaneous coronary intervention and two coronary artery bypass surgeries. ISR is possibly associated with extra-stent, stent-related and intra-stent factors. Here, we excluded the first two and focused on the intra-stent factors that seem more likely in our case. A challenging diagnostic workup led us to the hypothesis of a coronary vasculitis potentially triggered by some component of the stent in a predisposed patient carrier of non-disease-specific ANA, with an exaggerated immune response. No recurrence of ISR occurred after the introduction of steroids. Biological and intra-stent causes of ISR should be taken into careful consideration to aim for the early detection of the underlying mechanism of restenosis and to embrace the best therapeutic strategy.

View the entire article

Downloads

References

  1. Hu W, Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front Bioeng Biotechnol 2022;10:1003322.
  2. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv 2019;12: e007023.
  3. Pepe M, Napoli G, Carulli E, Moscarelli M, Forleo C, Nestola PL, et al. Autoimmune diseases in patients undergoing percutaneous coronary intervention: a risk factor for in-stent restenosis? Atherosclerosis 2021;333:24–31.
  4. Schur PH. Laboratory testing for the diagnosis, evaluation, and management of systemic lupus erythematosus: still more questions for the next generations: a tribute and thanks and in memory of my mentor: Henry G. Kunkel. Clin Immunol 2016;172:117–121.
  5. Chioncel V, Andrei CL, Brezeanu R, Sinescu C, Avram A, Tatu AL. Some perspectives on hypersensitivity to coronary stents. Int J Gen Med 2021;14:4327–4336.
  6. Omeh DJ, Shlofmitz E. Restenosis of stented coronary arteries. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
  7. Bazyani A, Simion P, Anghel L, Statescu C, Tinica G. Multiple in-stent restenosis. a rare cause of resistance to antiproliferative drugs? Maedica (Bucur) 2019;14:38–44.
  8. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103–e123.
  9. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis 2016;8:E1150–E1162.
  10. Slodownik D, Danenberg C, Merkin D, Swaid F, Moshe S, Ingber A, et al. Coronary stent restenosis and the association with allergy to metal content of 316L stainless steel. Cardiovasc J Afr 2018;29:43–45.
  11. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897–1907.
  12. Khanna S, Garikapati K, Goh DSL, Cho K, Lo P, Bhojaraja MV, et al. Coronary artery vasculitis: a review of current literature. BMC Cardiovasc Disord 2021;21:7.
  13. Kikuchi S, Okada K, Hibi K, Maejima N, Yabu N, Uchida K, et al. Coronary arteritis: a case series. Eur Heart J Case Rep 2020;4:1–6.
  14. Yoon S-O, Roux PP. Rapamycin resistance: mTORC1 substrates hold some of the answers. Curr Biol 2013;23:R880–883.
  15. Koch W, Böttiger C, Mehilli J, von Beckerath N, Neumann FJ, Schömig A, et al. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 2001;88:1120–1124.
  16. Fitridge R, Thompson M, editors. Mechanisms of vascular disease: a reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press; 2011.
  17. Kazemian MR, Solouk A, Tan A, Seifalian AM. Preventing in-stent restenosis using lipoprotein (a), lipid and cholesterol adsorbent materials. Med Hypotheses 2015;85:986–988.

Published

2024-04-05

Issue

Vol. 11 No. 5 (2024)

Categories

How to Cite

1.
Tomberli B, Fumagalli S, Minopoli TC, Menale S, Scheggi V, Marchionni N. Recurrent intra-stent coronary restenosis in a carrier of non-disease-specific antinuclear antibodies. EJCRIM [Internet]. 2024 Apr. 5 [cited 2026 Nov. 3];11(5). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4412